Pub Date : 2017-06-01DOI: 10.1097/POC.0000000000000131
J. Bolodeoku., S. Bains, Vivek Chand, R. Bacon, P. Weir, V. Miles, F. Chinegwundoh
Background This study evaluated and compared the performance of the i-CHROMA point-of-care testing (POCT) method for the quantification of prostate-specific antigen (PSA) against a traditional laboratory PSA method (Abbott Architect assay). Materials and Method Blood samples (venous [143] serum [143]) and finger prick (55) were collected from volunteers at a PSA screening campaign. Both venous and finger-prick samples were analyzed using the i-CHROMA PSA method and serum samples using the Abbott Architect method. Results were compared using linear regression and Red Amber Green analysis, a scoring system based on volunteer's age and PSA level. Red indicated a raised PSA, amber indicated a slightly raised PSA, and green indicated a normal PSA. Results The data showed that both the i-CHROMA PSA results using the venous samples (r2 = 0.9841) and the finger-prick samples (r2 = 0.90845) showed a good correlation when compared with the serum samples using the laboratory method. The Red Amber Green analysis showed the i-CHROMA' venous PSA method identified 15 reds, 13 ambers, and 115 greens compared with 9 reds, 8 ambers, and 126 greens identified by Abbot Architect method. The i-CHROMA finger-prick PSA method identified 3 reds, 3 ambers, and 49 greens compared with 3 reds, 1 ambers, and 51 greens identified by Abbot Architect method. Conclusions The i-CHROMA POCT PSA method showed good correlation with the Abbott Architect PSA method. Higher numbers of raised and abnormal PSA were identified by the i-CHROMA POCT PSA method due to the positive bias observed. The i-CHROMA POCT PSA method is a reliable method for total PSA within its limitations.
{"title":"An Evaluation of the Point-of-Care Test i-CHROMA Prostate-Specific Antigen Method for Screening in the Community","authors":"J. Bolodeoku., S. Bains, Vivek Chand, R. Bacon, P. Weir, V. Miles, F. Chinegwundoh","doi":"10.1097/POC.0000000000000131","DOIUrl":"https://doi.org/10.1097/POC.0000000000000131","url":null,"abstract":"Background This study evaluated and compared the performance of the i-CHROMA point-of-care testing (POCT) method for the quantification of prostate-specific antigen (PSA) against a traditional laboratory PSA method (Abbott Architect assay). Materials and Method Blood samples (venous [143] serum [143]) and finger prick (55) were collected from volunteers at a PSA screening campaign. Both venous and finger-prick samples were analyzed using the i-CHROMA PSA method and serum samples using the Abbott Architect method. Results were compared using linear regression and Red Amber Green analysis, a scoring system based on volunteer's age and PSA level. Red indicated a raised PSA, amber indicated a slightly raised PSA, and green indicated a normal PSA. Results The data showed that both the i-CHROMA PSA results using the venous samples (r2 = 0.9841) and the finger-prick samples (r2 = 0.90845) showed a good correlation when compared with the serum samples using the laboratory method. The Red Amber Green analysis showed the i-CHROMA' venous PSA method identified 15 reds, 13 ambers, and 115 greens compared with 9 reds, 8 ambers, and 126 greens identified by Abbot Architect method. The i-CHROMA finger-prick PSA method identified 3 reds, 3 ambers, and 49 greens compared with 3 reds, 1 ambers, and 51 greens identified by Abbot Architect method. Conclusions The i-CHROMA POCT PSA method showed good correlation with the Abbott Architect PSA method. Higher numbers of raised and abnormal PSA were identified by the i-CHROMA POCT PSA method due to the positive bias observed. The i-CHROMA POCT PSA method is a reliable method for total PSA within its limitations.","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84123774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-01DOI: 10.1097/POC.0000000000000136
E. Lee-Lewandrowski, J. Flood, R. Zak, David A Griggs, K. Lewandrowski
Abstract In this study, we performed method validations for the Abaxis Piccolo Xpress assays for total protein, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, calcium, creatinine, urea nitrogen, and glucose compared with the Roche Cobas c501 analyzer. The validation included linear reportable range, imprecision, and assessment of accuracy and bias by method crossover. Although some biases between the methods were observed, these could be reconciled by adjustments to the normal reference ranges. Overall, we found that these assays performed at an accepted level for clinical use.
在本研究中，我们对Abaxis Piccolo Xpress检测总蛋白、白蛋白、丙氨酸转氨酶、天冬氨酸转氨酶、碱性磷酸酶、总胆红素、钙、肌酐、尿素氮和葡萄糖的方法进行了验证，并与罗氏Cobas c501分析仪进行了比较。验证包括线性报告范围、不精确性以及通过方法交叉评估准确性和偏倚。虽然观察到方法之间存在一些偏差，但这些偏差可以通过调整正常参考范围来调和。总的来说，我们发现这些检测在临床应用中处于可接受的水平。
{"title":"Evaluation of the Abaxis Piccolo Point-of-Care Chemistry Analyzer: Comparison to the Roche Cobas C501","authors":"E. Lee-Lewandrowski, J. Flood, R. Zak, David A Griggs, K. Lewandrowski","doi":"10.1097/POC.0000000000000136","DOIUrl":"https://doi.org/10.1097/POC.0000000000000136","url":null,"abstract":"Abstract In this study, we performed method validations for the Abaxis Piccolo Xpress assays for total protein, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, calcium, creatinine, urea nitrogen, and glucose compared with the Roche Cobas c501 analyzer. The validation included linear reportable range, imprecision, and assessment of accuracy and bias by method crossover. Although some biases between the methods were observed, these could be reconciled by adjustments to the normal reference ranges. Overall, we found that these assays performed at an accepted level for clinical use.","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83133874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-01DOI: 10.1097/POC.0000000000000129
Annika Eriksson
Abstract Diabetes care is complex requiring prevention and management to minimize complications. Point-of-care testing (POCT) has been found to have a positive impact on diabetes management, and studies have described an improvement in patient satisfaction and glycemic control as a result of immediate feedback to the patient. The HemoCue POCT technology directed toward diabetes management includes glucose and hemoglobin A1c devices as well as urine analyses to screen for microalbuminuria and nephropathy. HemoCue offers laboratory-accurate POCT solutions that are fast and easy to use with factory-calibrated analyzers and minimum maintenance required. With data management solutions, patient safety can be optimized making sure that the right tests are performed by the right person for the right patient.
{"title":"The HemoCue Glucose, Albumin, and Hemoglobin A1c Systems: Enable Right Decisions at the Point of Care","authors":"Annika Eriksson","doi":"10.1097/POC.0000000000000129","DOIUrl":"https://doi.org/10.1097/POC.0000000000000129","url":null,"abstract":"Abstract Diabetes care is complex requiring prevention and management to minimize complications. Point-of-care testing (POCT) has been found to have a positive impact on diabetes management, and studies have described an improvement in patient satisfaction and glycemic control as a result of immediate feedback to the patient. The HemoCue POCT technology directed toward diabetes management includes glucose and hemoglobin A1c devices as well as urine analyses to screen for microalbuminuria and nephropathy. HemoCue offers laboratory-accurate POCT solutions that are fast and easy to use with factory-calibrated analyzers and minimum maintenance required. With data management solutions, patient safety can be optimized making sure that the right tests are performed by the right person for the right patient.","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89530068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-01DOI: 10.1097/POC.0000000000000122
G. Kost, Busadee Pratumvinit
Abstract In limited-resource settings, prediabetes and diabetes care demand efficient Spatial Care Paths and effective geospatial optimization of medical services upstream to avoid the economic penalties of untold patient complications downstream. Clever HbA1c technologies placed at the leading edge of primary care in health care small-world networks will improve patient care where multifactorial impediments are identified by facilitation thresholds. We illustrate how to formulate facilitation thresholds and then actuate changes that will solve problems generating the threshold phenomena. It is no longer a question of whether point-of-care HbA1c should be used, in view of numerous studies showing its benefits that we summarize, but instead one of how to effectively design, implement, integrate, and optimize strategies that serve underserved populations. In parallel, professional oversight for HbA1c interferences and variants accompanied by laboratory evaluation will help optimize diagnosis and monitoring. Aerial drones, which currently are used to deliver blood, vaccines, and drugs to inaccessible rural settings, could transport specimens for detailed HbA1c evaluations. By taking advantage of strategic intelligence and moving to primary care, the flow of knowledge emanating directly from patients will help public health nurses, primary care staff, and multidisciplinary physicians, some working via telemedicine, to proactively and preemptively reduce diabetes complications by means of evidence-based, cost-effective decision making closer to patient homes. Innovative monitoring and treatment will fulfill expectations for high-quality efficient personalized care, even self-monitoring essential to the management of a chronic condition, thus transforming standards of care to appropriately embrace and empower point-of-care culture.
{"title":"Diabetes Spatial Care Paths, Leading Edge HbA1c Testing, Facilitation Thresholds, Proactive-Preemptive Strategic Intelligence, and Unmanned Aerial Vehicles in Limited-Resource Countries","authors":"G. Kost, Busadee Pratumvinit","doi":"10.1097/POC.0000000000000122","DOIUrl":"https://doi.org/10.1097/POC.0000000000000122","url":null,"abstract":"Abstract In limited-resource settings, prediabetes and diabetes care demand efficient Spatial Care Paths and effective geospatial optimization of medical services upstream to avoid the economic penalties of untold patient complications downstream. Clever HbA1c technologies placed at the leading edge of primary care in health care small-world networks will improve patient care where multifactorial impediments are identified by facilitation thresholds. We illustrate how to formulate facilitation thresholds and then actuate changes that will solve problems generating the threshold phenomena. It is no longer a question of whether point-of-care HbA1c should be used, in view of numerous studies showing its benefits that we summarize, but instead one of how to effectively design, implement, integrate, and optimize strategies that serve underserved populations. In parallel, professional oversight for HbA1c interferences and variants accompanied by laboratory evaluation will help optimize diagnosis and monitoring. Aerial drones, which currently are used to deliver blood, vaccines, and drugs to inaccessible rural settings, could transport specimens for detailed HbA1c evaluations. By taking advantage of strategic intelligence and moving to primary care, the flow of knowledge emanating directly from patients will help public health nurses, primary care staff, and multidisciplinary physicians, some working via telemedicine, to proactively and preemptively reduce diabetes complications by means of evidence-based, cost-effective decision making closer to patient homes. Innovative monitoring and treatment will fulfill expectations for high-quality efficient personalized care, even self-monitoring essential to the management of a chronic condition, thus transforming standards of care to appropriately embrace and empower point-of-care culture.","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84914199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-01DOI: 10.1097/POC.0000000000000124
K. Lewandrowski
{"title":"The Clinical Utility of Urinary Microalbumin in the Management of Diabetes Mellitus","authors":"K. Lewandrowski","doi":"10.1097/POC.0000000000000124","DOIUrl":"https://doi.org/10.1097/POC.0000000000000124","url":null,"abstract":"","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84090057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-01DOI: 10.1097/POC.0000000000000123
K. Lewandrowski
{"title":"Lipid Testing in Patients With Diabetes Mellitus Typ. 2","authors":"K. Lewandrowski","doi":"10.1097/POC.0000000000000123","DOIUrl":"https://doi.org/10.1097/POC.0000000000000123","url":null,"abstract":"","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86533783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-01DOI: 10.1097/POC.0000000000000127
J. Dubois, A. Malic
Abstract Glucose meter accuracy is vital to achieve safe and effective glycemic control in critically ill patients but can be compromised by endogenous and exogenous interferences that are common in this patient population. The StatStrip Glucose Hospital Meter System is a point-of-care, handheld blood glucose monitoring system that was specifically designed to automatically correct for interferences and provide accuracy comparable to the central laboratory. StatStrip Glucose is the only blood glucose monitoring system to be cleared by the Food and Drug Administration as accurate enough for use with all patients including the critically ill. Extensive analysis has proven that StatStrip Glucose improves glycemic control, patient outcomes, and test utilization. StatStrip Glucose does not require calibration coding and provides comprehensive networking and connectivity and extensive user training.
{"title":"The StatStrip Glucose Hospital Meter System: Point-of-Care Testing in Critically Ill Patients","authors":"J. Dubois, A. Malic","doi":"10.1097/POC.0000000000000127","DOIUrl":"https://doi.org/10.1097/POC.0000000000000127","url":null,"abstract":"Abstract Glucose meter accuracy is vital to achieve safe and effective glycemic control in critically ill patients but can be compromised by endogenous and exogenous interferences that are common in this patient population. The StatStrip Glucose Hospital Meter System is a point-of-care, handheld blood glucose monitoring system that was specifically designed to automatically correct for interferences and provide accuracy comparable to the central laboratory. StatStrip Glucose is the only blood glucose monitoring system to be cleared by the Food and Drug Administration as accurate enough for use with all patients including the critically ill. Extensive analysis has proven that StatStrip Glucose improves glycemic control, patient outcomes, and test utilization. StatStrip Glucose does not require calibration coding and provides comprehensive networking and connectivity and extensive user training.","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80105583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-01DOI: 10.1097/POC.0000000000000119
K. Lewandrowski
{"title":"Capillary Blood Glucose Meters in the Home, Clinic, and Hospital","authors":"K. Lewandrowski","doi":"10.1097/POC.0000000000000119","DOIUrl":"https://doi.org/10.1097/POC.0000000000000119","url":null,"abstract":"","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83171131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-01DOI: 10.1097/POC.0000000000000126
Mark Andrews
P roviding patients the best possible care is a top priority for point-of-care (POC) health care professionals throughout the United States. The availability of a user-friendly, handheld, wireless POC solution for monitoring blood glucose levels makes this not only feasible, but also essential. Since 1982, Roche has been a provider of industry-leading professional-use blood glucose monitoring solutions. Beginning with the Accu-Chek bG Blood Glucose Monitor and continuing with the 2012 launch of the CLIA-waived Accu-Chek Inform II system, Roche and the Accu-Chek brand are committed to providing real innovation in patient care, connectivity, and durability at the point of care.
{"title":"The Accu-Chek Inform II Blood Glucose Monitoring System","authors":"Mark Andrews","doi":"10.1097/POC.0000000000000126","DOIUrl":"https://doi.org/10.1097/POC.0000000000000126","url":null,"abstract":"P roviding patients the best possible care is a top priority for point-of-care (POC) health care professionals throughout the United States. The availability of a user-friendly, handheld, wireless POC solution for monitoring blood glucose levels makes this not only feasible, but also essential. Since 1982, Roche has been a provider of industry-leading professional-use blood glucose monitoring solutions. Beginning with the Accu-Chek bG Blood Glucose Monitor and continuing with the 2012 launch of the CLIA-waived Accu-Chek Inform II system, Roche and the Accu-Chek brand are committed to providing real innovation in patient care, connectivity, and durability at the point of care.","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75290983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-01DOI: 10.1097/POC.0000000000000121
P. Sluss
{"title":"Hemoglobin A1c Testing in Patients With Diabetes","authors":"P. Sluss","doi":"10.1097/POC.0000000000000121","DOIUrl":"https://doi.org/10.1097/POC.0000000000000121","url":null,"abstract":"","PeriodicalId":20262,"journal":{"name":"Point of Care: The Journal of Near-Patient Testing & Technology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78932450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：